Table 1.
Patient and disease characteristics.
| Characteristics | Total | CAR | p-value | CFA | p-value | mGPS | p-value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low-CAR (<0.387) |
High-CAR (≥0.387) |
Low-CFA (<0.396) |
High-CFA (≥0.396) |
mGPS0 | mGPS1 | mGPS2 | |||||
| Number of patients, n (%) | 74 | 42 (56.8%) | 32 (43.2%) | – | 34 (45.9%) | 40 (54.1%) | – | 38 (51.4%) | 15 (20.3%) | 21 (28.4%) | – |
| Age (years), n (%) | 0.090 | 0.230 | 0.275 | ||||||||
| <35 | 46 (62.2%) | 30 (71.4%) | 16 (50%) | 24 (70.6%) | 22 (55.0%) | 27 (71.1%) | 8 (53.3%) | 11 (52.4%) | |||
| ≥35 | 28 (37.8%) | 12 (28.6%) | 16 (50%) | 10 (29.4%) | 18 (45.0%) | 11 (28.9%) | 7 (46.7%) | 10 (47.6%) | |||
| Gender, n (%) | 0.194 | 0.190 | 0.118 | ||||||||
| Male | 54 (73.0%) | 28 (66.7%) | 26 (81.3%) | 22 (64.7%) | 32 (80.0%) | 25 (65.8%) | 14 (93.3%) | 15 (71.4%) | |||
| Female | 20 (27.0%) | 14 (33.3%) | 6 (18.8%) | 12 (35.3%) | 8 (20.0%) | 13 (34.2%) | 1 (6.7%) | 6 (28.6%) | |||
| WBC (109/L), n (%) | 0.005 | 0.004 | 0.017 | ||||||||
| WBC < 100 | 52 (70.3%) | 24 (57.1%) | 28 (87.5%) | 18 (52.9%) | 34 (85.0%) | 21 (55.3%) | 13 (86.7%) | 18 (85.7%) | |||
| WBC ≥ 100 | 22 (29.7%) | 18 (42.9%) | 4 (12.5%) | 16 (47.1%) | 6 (15.0%) | 17 (44.7%) | 2 (13.3%) | 3 (14.3%) | |||
| HGB (g/L), median (range) | 94 (48–173) | 111 (48–173) | 80 (50–162) | 0.070 | 99 (48–173) | 89 (50–162) | 0.262 | 111 (48–173) | 96 (52–146) | 81 (50–162) | 0.259 |
| PLT (109/L), median (range) | 62 (4–382) | 54 (7–382) | 67.5 (4–296) | 0.462 | 70 (7–382) | 61.5 (4–296) | 0.925 | 60 (7–382) | 64 (8–152) | 61 (4–296) | 0.905 |
| CRP (mg/L), median (range) | 7.10 (0.24–102) | 3.23 (0.24–14.88) | 33.09 (10.99–102) | <0.001 | 2.55 (0.24–7.06) | 22.48 (4.58–102) | <0.001 | 3.02 (0.24–7.10) | 18.90 (13.09–78.6) | 33.68 (10.99–102) | <0.001 |
| ALB (g/L), median (range) | 36.5 (25.0–45.5) | 37.5 (27.8–45.5) | 32.8 (25.0–44.6) | 0.004 | 37.5 (27.8–45.5) | 33.85 (25.0–44.6) | 0.006 | 37.5 (27.8–45.5) | 39.0 (35.0–44.6) | 31.2 (25.0–34.7) | <0.001 |
| Fib (g/L), median (range) | 2.58 (0.60–6.79) | 2.11 (0.73–5.80) | 2.90 (0.60–6.79) | 0.025 | 2.02 (0.73–5.80) | 2.94 (0.60–6.79) | <0.001 | 2.03 (0.73–5.80) | 3.14 (0.60–6.32) | 2.79 (1.64–6.79) | 0.009 |
| BMI (kg/m2), median (range) | 23.2 (14.5–33.7) | 23.0 (14.5–32.0) | 23.4 (18.3–33.7) | 0.464 | 22.3 (14.5–32.0) | 23.4 (17.5–33.7) | 0.259 | 23.0 (14.5–32.0) | 23.5 (18.7–29.1) | 23.3 (18.3–33.7) | 0.573 |
| Immunophenotype, n (%) | 0.254 | 0.080 | 0.181 | ||||||||
| ETP-ALL | 14 (18.9%) | 6 (14.3%) | 8 (25.0%) | 4 (11.8%) | 10 (25.0%) | 5 (13.2%) | 6 (40.0%) | 3 (14.3%) | |||
| Pro/Pre-T-ALL | 32 (43.2%) | 16 (38.1%) | 16 (50%) | 12 (35.3%) | 20 (50.0%) | 14 (36.8%) | 5 (33.3%) | 13 (61.9%) | |||
| Cortical/Medullary T-ALL | 14 (18.9%) | 10 (23.8%) | 4 (12.5%) | 8 (23.5%) | 6 (15.0%) | 9 (23.7%) | 2 (13.3%) | 3 (14.3%) | |||
| Unclassified | 14 (18.9%) | 10 (23.8%) | 4 (12.5%) | 10 (29.4%) | 4 (10.0%) | 10 (26.3%) | 2 (13.3%) | 2 (9.5%) | |||
| Genetics1, (%) | |||||||||||
| NOTCH1 | 30/61 (49.2%) | 17/36 (47.2%) | 13/25 (52.0%) | 0.797 | 15/30 (50.0%) | 15/31 (48.4%) | 1.000 | 16/33 (48.5%) | 7/13 (53.8%) | 7/15 (46.7%) | 1.000 |
| FBWX7 | 8/61 (13.1%) | 5/36 (13.9%) | 3/25 (12.0%) | 1.000 | 4/30 (13.3%) | 4/31 (12.9%) | 1.000 | 5/33 (15.2%) | 1/13 (7.7%) | 2/15 (13.3%) | 0.886 |
| RAS | 14/61 (23.0%) | 6/36 (16.7%) | 8/25 (32.0%) | 0.219 | 6/30 (20.0%) | 8/31 (25.8%) | 0.762 | 6/33 (18.2%) | 4/13 (30.8%) | 4/15 (26.7%) | 0.606 |
| PTEN | 9/61 (14.8%) | 7/36 (19.4%) | 2/25 (8.0%) | 0.286 | 6/30 (20%) | 3/31 (9.7%) | 0.301 | 7/33 (21.2%) | 0/13 (0%) | 2/15 (13.3%) | 0.238 |
| Temperature ≥38.5 °C pre-IC, n (%) | 15 (20.3%) | 6 (14.3%) | 9 (28.1%) | 0.120 | 5 (14.7%) | 10 (25.0%) | 0.211 | 5 (13.2%) | 4 (26.7%) | 6 (28.6%) | 0.258 |
| Anti-infective therapy pre-IC, n (%) | 50 (67.6%) | 26 (61.9%) | 24 (75.0%) | 0.317 | 21 (61.8%) | 29 (72.5%) | 0.455 | 23 (60.5%) | 12 (80.0%) | 15 (71.4%) | 0.389 |
| HSCT2, n (%) | 24/63 (38.1%) | 17/42 (40.5%) | 7/21 (33.3%) | 0.784 | 17/34 (50.0%) | 7/29 (24.1%) | 0.042 | 17/38 (44.7%) | 4/12 (33.3%) | 3/13 (23.1%) | 0.365 |
| CR/CRi attainment at EOI, n (%) | 49 (66.2%) | 36 (85.7%) | 13 (40.6%) | <0.001 | 31 (91.2%) | 18 (45.0%) | <0.001 | 34 (89.5%) | 7 (46.7%) | 8 (38.1%) | <0.001 |
| MRD < 0.1% at EOI, n (%) | 30 (40.5%) | 24 (57.1%) | 6 (18.8%) | <0.001 | 20 (58.8%) | 10 (25.0%) | 0.004 | 23 (60.5%) | 4 (26.7%) | 3 (14.3%) | <0.001 |
| Relapse3, n (%) | 26/63 (41.4%) | 17/42 (40.5%) | 9/21 (42.9%) | 1.000 | 13/34 (38.3%) | 13/29 (44.8%) | 0.618 | 14/38 (36.8%) | 5/12 (41.7%) | 7/13 (53.8%) | 0.592 |
| Follow-up (months), median (range) | 48.2 (0.58–130.4) | 48.2 (7.1–130.4) | 49.0 (0.58–127.7) | 0.777 | 42.8 (7.1–120.1) | 50.1 (0.58–130.4) | 0.199 | 48.2 (7.1–130.4) | 27.6 (0.58–74.9) | 49.0 (1.1–127.7) | 0.185 |
1Genetic mutation results were available for 61 of the 74 patients.
2Data on patients undergoing HSCT among the 63 achieving CR.
3Data from relapsed patients among 63 CR cases.
CAR, C-reactive protein to albumin ratio; CFA, CRP×fibrinogen/albumin ratio; mGPS, modified glasgow prognostic score; HGB, hemoglobin; PLT, platelet; CRP, C-reactive protein; ALB, albumin; Fib, fibrinogen; BMI, body mass index; ETP, early thymic precursor; IC, induction chemotherapy; HSCT, hematopoietic stem cell transplantation; CR, complete remission; CRi, CR with incomplete hematologic recovery; MRD, minimal residual disease; EOI, end-of-induction.